182 related articles for article (PubMed ID: 22189971)
1. Regulation of RUNX2 transcription factor-DNA interactions and cell proliferation by vitamin D3 (cholecalciferol) prohormone activity.
Underwood KF; D'Souza DR; Mochin-Peters M; Pierce AD; Kommineni S; Choe M; Bennett J; Gnatt A; Habtemariam B; MacKerell AD; Passaniti A
J Bone Miner Res; 2012 Apr; 27(4):913-25. PubMed ID: 22189971
[TBL] [Abstract][Full Text] [Related]
2. Functional cooperation between vitamin D receptor and Runx2 in vitamin D-induced vascular calcification.
Han MS; Che X; Cho GH; Park HR; Lim KE; Park NR; Jin JS; Jung YK; Jeong JH; Lee IK; Kato S; Choi JY
PLoS One; 2013; 8(12):e83584. PubMed ID: 24349534
[TBL] [Abstract][Full Text] [Related]
3. Singly dehydroxylated A-ring analogues of 19-nor-1alpha,25-dihydroxyvitamin D3 and 19-nor-22-oxa-1alpha,25-dihydroxyvitamin D3: novel vitamin D3 analogues with potent transcriptional activity but extremely low affinity for vitamin D receptor.
Okano T; Nakagawa K; Tsugawa N; Ozono K; Kubodera N; Osawa A; Terada M; Mikami K
Biol Pharm Bull; 1998 Dec; 21(12):1300-5. PubMed ID: 9881643
[TBL] [Abstract][Full Text] [Related]
4. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.
Mendoza-Villanueva D; Zeef L; Shore P
Breast Cancer Res; 2011 Oct; 13(5):R106. PubMed ID: 22032690
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D3 derivatives with adamantane or lactone ring side chains are cell type-selective vitamin D receptor modulators.
Inaba Y; Yamamoto K; Yoshimoto N; Matsunawa M; Uno S; Yamada S; Makishima M
Mol Pharmacol; 2007 May; 71(5):1298-311. PubMed ID: 17325131
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel melatonin-binding nuclear receptor: Vitamin D receptor.
Fang N; Hu C; Sun W; Xu Y; Gu Y; Wu L; Peng Q; Reiter RJ; Liu L
J Pineal Res; 2020 Jan; 68(1):e12618. PubMed ID: 31631405
[TBL] [Abstract][Full Text] [Related]
7. 20-Hydroxyvitamin D3, a product of vitamin D3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation.
Zbytek B; Janjetovic Z; Tuckey RC; Zmijewski MA; Sweatman TW; Jones E; Nguyen MN; Slominski AT
J Invest Dermatol; 2008 Sep; 128(9):2271-80. PubMed ID: 18368131
[TBL] [Abstract][Full Text] [Related]
8. 1α,25(OH)2-3-epi-vitamin D3, a natural physiological metabolite of vitamin D3: its synthesis, biological activity and crystal structure with its receptor.
Molnár F; Sigüeiro R; Sato Y; Araujo C; Schuster I; Antony P; Peluso J; Muller C; Mouriño A; Moras D; Rochel N
PLoS One; 2011 Mar; 6(3):e18124. PubMed ID: 21483824
[TBL] [Abstract][Full Text] [Related]
9. Induction of CFTR gene expression by 1,25(OH)
DiFranco KM; Mulligan JK; Sumal AS; Diamond G
J Steroid Biochem Mol Biol; 2017 Oct; 173():323-332. PubMed ID: 28130182
[TBL] [Abstract][Full Text] [Related]
10. Novel target genes of RUNX2 transcription factor and 1,25-dihydroxyvitamin D3.
Stephens AS; Morrison NA
J Cell Biochem; 2014 Sep; 115(9):1594-608. PubMed ID: 24756753
[TBL] [Abstract][Full Text] [Related]
11. Suppression of rat hepatic vitamin D-25-hydroxylase by cholecalciferol, but not by 25-hydroxy- or 1,25-dihydroxymetabolites.
Bolt MJ; Meredith SC; Rosenberg IH
Calcif Tissue Int; 1988 Apr; 42(4):273-8. PubMed ID: 2840181
[TBL] [Abstract][Full Text] [Related]
12. Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements.
Verlinden L; Verstuyf A; Quack M; Van Camp M; Van Etten E; De Clercq P; Vandewalle M; Carlberg C; Bouillon R
J Bone Miner Res; 2001 Apr; 16(4):625-38. PubMed ID: 11315990
[TBL] [Abstract][Full Text] [Related]
13. Modulation of mouse RANKL gene expression by Runx2 and vitamin D3.
Kitazawa R; Mori K; Yamaguchi A; Kondo T; Kitazawa S
J Cell Biochem; 2008 Dec; 105(5):1289-97. PubMed ID: 18814144
[TBL] [Abstract][Full Text] [Related]
14. The vitamin D3 1alpha-hydroxylase gene and its regulation by active vitamin D3.
Takeyama K; Kato S
Biosci Biotechnol Biochem; 2011; 75(2):208-13. PubMed ID: 21307571
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells.
Tokar EJ; Webber MM
Clin Exp Metastasis; 2005; 22(3):265-73. PubMed ID: 16158254
[TBL] [Abstract][Full Text] [Related]
16. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
Kim S; Shevde NK; Pike JW
J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
[TBL] [Abstract][Full Text] [Related]
17. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
18. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter.
Drissi H; Pouliot A; Koolloos C; Stein JL; Lian JB; Stein GS; van Wijnen AJ
Exp Cell Res; 2002 Apr; 274(2):323-33. PubMed ID: 11900492
[TBL] [Abstract][Full Text] [Related]
19. Potent antiproliferative effects of 25-hydroxy-16-ene-23-yne-vitamin D₃ that resists the catalytic activity of both CYP27B1 and CYP24A1.
Rhieu SY; Annalora AJ; LaPorta E; Welsh J; Itoh T; Yamamoto K; Sakaki T; Chen TC; Uskokovic MR; Reddy GS
J Cell Biochem; 2014 Aug; 115(8):1392-402. PubMed ID: 24535953
[TBL] [Abstract][Full Text] [Related]
20. 25-Hydroxyvitamin D Inhibits Hepatitis C Virus Production in Hepatocellular Carcinoma Cell Line by a Vitamin D Receptor-Independent Mechanism.
Ravid A; Rapaport N; Issachar A; Erman A; Bachmetov L; Tur-Kaspa R; Zemel R
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31086078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
